Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4413943 | 0.85 | KMT2A (0.47) | KMT2AEPHX2HDAC1HDAC3HDAC2 | |
| SCHEMBL16256817 | 0.85 | KMT2A (0.52) | KMT2AEPHX2LMNACASP3 | |
| SCHEMBL15946357 | 0.84 | EPHX2 (0.56) | KMT2AEPHX2RAB9ACASP3 | |
| SCHEMBL32671446 | 0.84 | KMT2A (0.51) | KMT2AEPHX2HDAC1CASP3NAMPT | |
| SCHEMBL14485472 | 0.84 | KMT2A (0.51) | KMT2AEPHX2HDAC1CASP3NAMPT | |
| SCHEMBL118108 | 0.83 | KMT2A (0.56) | KMT2AEPHX2CASP3 | |
| SCHEMBL29678978 | 0.83 | KMT2A (0.56) | KMT2AEPHX2CASP3 | |
| SCHEMBL29402075 | 0.83 | KMT2A (0.56) | KMT2AEPHX2CASP3 | |
| SCHEMBL20415024 | 0.83 | KMT2A (0.52) | KMT2AHDAC1HDAC2NAMPTHDAC6 | |
| SCHEMBL15948331 | 0.82 | KMT2A (0.53) | KMT2AEPHX2HDAC1HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9464064-B2 | HCV helicase inhibitors and methods of use thereof | UNIVERSITY OF KANSAS (US) | 2016-10-11 | — | — | US | disclosed |
| US-20140227225-A1 | HCV Helicase Inhibitors and Methods of Use Thereof | UWM RESEARCH FOUNDATION, INC. (US) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140227225-A1 | HCV Helicase Inhibitors and Methods of Use Thereof | DHX15, DDX5, DHX35 | KMT2A 3831/4885EPHX2 524/4885LMNA 2452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.